These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 19652526)

  • 1. Death receptor 5 agonist TRA8 in combination with the bisphosphonate zoledronic acid attenuated the growth of breast cancer metastasis.
    Szafran AA; Folks K; Warram J; Chanda D; Wang D; Zinn KR
    Cancer Biol Ther; 2009 Jun; 8(12):1109-16. PubMed ID: 19652526
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antitumor effects of clinical dosing regimens of bisphosphonates in experimental breast cancer bone metastasis.
    Daubiné F; Le Gall C; Gasser J; Green J; Clézardin P
    J Natl Cancer Inst; 2007 Feb; 99(4):322-30. PubMed ID: 17312309
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The activity of zoledronic Acid on neuroblastoma bone metastasis involves inhibition of osteoclasts and tumor cell survival and proliferation.
    Peng H; Sohara Y; Moats RA; Nelson MD; Groshen SG; Ye W; Reynolds CP; DeClerck YA
    Cancer Res; 2007 Oct; 67(19):9346-55. PubMed ID: 17909043
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preventive effects of zoledronic acid on bone metastasis in mice injected with human breast cancer cells.
    Jeong J; Lee KS; Choi YK; Oh YJ; Lee HD
    J Korean Med Sci; 2011 Dec; 26(12):1569-75. PubMed ID: 22147993
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anticancer mechanisms of doxorubicin and zoledronic acid in breast cancer tumor growth in bone.
    Ottewell PD; Woodward JK; Lefley DV; Evans CA; Coleman RE; Holen I
    Mol Cancer Ther; 2009 Oct; 8(10):2821-32. PubMed ID: 19789217
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of zoledronic acid on the doxycycline-induced decrease in tumour burden in a bone metastasis model of human breast cancer.
    Duivenvoorden WC; Vukmirović-Popović S; Kalina M; Seidlitz E; Singh G
    Br J Cancer; 2007 May; 96(10):1526-31. PubMed ID: 17437017
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The combined use of Camellia sinensis and metronomic zoledronic acid in a breast cancer-induced osteolysis mouse model.
    Luo KW; Ko CH; Yue GG; Gao S; Lee JK; Li G; Fung KP; Leung PC; Evdokiou A; Lau CB
    J Cancer Res Clin Oncol; 2015 Jun; 141(6):1025-36. PubMed ID: 25431338
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antitumor effects of doxorubicin followed by zoledronic acid in a mouse model of breast cancer.
    Ottewell PD; Mönkkönen H; Jones M; Lefley DV; Coleman RE; Holen I
    J Natl Cancer Inst; 2008 Aug; 100(16):1167-78. PubMed ID: 18695136
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aromatase inhibitor-induced bone loss increases the progression of estrogen receptor-negative breast cancer in bone and exacerbates muscle weakness in vivo.
    Wright LE; Harhash AA; Kozlow WM; Waning DL; Regan JN; She Y; John SK; Murthy S; Niewolna M; Marks AR; Mohammad KS; Guise TA
    Oncotarget; 2017 Jan; 8(5):8406-8419. PubMed ID: 28039445
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antagonism of inhibitor of apoptosis proteins increases bone metastasis via unexpected osteoclast activation.
    Yang C; Davis JL; Zeng R; Vora P; Su X; Collins LI; Vangveravong S; Mach RH; Piwnica-Worms D; Weilbaecher KN; Faccio R; Novack DV
    Cancer Discov; 2013 Feb; 3(2):212-23. PubMed ID: 23269702
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential effect of doxorubicin and zoledronic acid on intraosseous versus extraosseous breast tumor growth in vivo.
    Ottewell PD; Deux B; Mönkkönen H; Cross S; Coleman RE; Clezardin P; Holen I
    Clin Cancer Res; 2008 Jul; 14(14):4658-66. PubMed ID: 18628481
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modifying the osteoblastic niche with zoledronic acid in vivo-potential implications for breast cancer bone metastasis.
    Haider MT; Holen I; Dear TN; Hunter K; Brown HK
    Bone; 2014 Sep; 66(100):240-50. PubMed ID: 24971713
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Zoledronic acid decreased osteolysis but not bone metastasis in a nude mouse model of canine prostate cancer with mixed bone lesions.
    Thudi NK; Martin CK; Nadella MV; Fernandez SA; Werbeck JL; Pinzone JJ; Rosol TJ
    Prostate; 2008 Jul; 68(10):1116-25. PubMed ID: 18461562
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preclinical studies with zoledronic acid and other bisphosphonates: impact on the bone microenvironment.
    Mundy GR; Yoneda T; Hiraga T
    Semin Oncol; 2001 Apr; 28(2 Suppl 6):35-44. PubMed ID: 11346863
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Zoledronic acid has differential antitumor activity in the pre- and postmenopausal bone microenvironment in vivo.
    Ottewell PD; Wang N; Brown HK; Reeves KJ; Fowles CA; Croucher PI; Eaton CL; Holen I
    Clin Cancer Res; 2014 Jun; 20(11):2922-32. PubMed ID: 24687923
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Survival benefit with radium-223 dichloride in a mouse model of breast cancer bone metastasis.
    Suominen MI; Rissanen JP; Käkönen R; Fagerlund KM; Alhoniemi E; Mumberg D; Ziegelbauer K; Halleen JM; Käkönen SM; Scholz A
    J Natl Cancer Inst; 2013 Jun; 105(12):908-16. PubMed ID: 23682134
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of the combined use of metronomic zoledronic acid and Coriolus versicolor in intratibial breast cancer mouse model.
    Ko CH; Yue GG; Gao S; Luo KW; Siu WS; Shum WT; Shiu HT; Lee JK; Li G; Leung PC; Evdokiou A; Lau CB
    J Ethnopharmacol; 2017 May; 204():77-85. PubMed ID: 28412218
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of zoledronic acid in the adjuvant treatment of breast cancer: current perspectives.
    Tonyali O; Arslan C; Altundag K
    Expert Opin Pharmacother; 2010 Nov; 11(16):2715-25. PubMed ID: 20977404
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structural simulation of adenosine phosphate via plumbagin and zoledronic acid competitively targets JNK/Erk to synergistically attenuate osteoclastogenesis in a breast cancer model.
    Qiao H; Wang TY; Yu ZF; Han XG; Liu XQ; Wang YG; Fan QM; Qin A; Tang TT
    Cell Death Dis; 2016 Feb; 7(2):e2094. PubMed ID: 26866274
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adoptive transfer of ex vivo expanded Vγ9Vδ2 T cells in combination with zoledronic acid inhibits cancer growth and limits osteolysis in a murine model of osteolytic breast cancer.
    Zysk A; DeNichilo MO; Panagopoulos V; Zinonos I; Liapis V; Hay S; Ingman W; Ponomarev V; Atkins G; Findlay D; Zannettino A; Evdokiou A
    Cancer Lett; 2017 Feb; 386():141-150. PubMed ID: 27865798
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.